**Supplement**

**Supplementary Table 1. Results of first survey.** The first survey aimed to establish the state-of-the-art in CPG routine care regarding diagnostics. A total of 29 European experts and 8 US experts completed the survey between July 2018 and April 2019. The number of affirmative answer and its percentages are shown for each item. A high agreement (>75%) was found in many statements.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **ALL** | **EUROPE** | **USA** |
|  | **n** | **%** | **n** | **%** | **n** | **%** |
| **I. MEDICAL HISTORY** |
| **1. CPG-related history** |   |   |   |   |   |   |
| **When did it begin? (Duration of disease)** | 37.0 | **100.0** | 29.0 | 100.0 | 8.0 | 100.0 |
| **Where did it begin? (Localization on the skin** | 35.0 | **94.6** | 28.0 | 96.6 | 7.0 | 87.5 |
| **Where is it now? (Localization on the skin)** | 32.0 | **86.5** | 25.0 | 86.2 | 7.0 | 87.5 |
| **Did the itch begin on visibly normal looking skin or were lesions already present when the itch began?** | 29.0 | **78.4** | 23.0 | 79.3 | 6.0 | 75.0 |
| **How did the lesions initially look?** | 27.0 | 73.0 | 22.0 | 75.9 | 5.0 | 62.5 |
| **Which general or dermatological disease occurred together with the prurigo?** | 30.0 | **81.1** | 25.0 | 86.2 | 5.0 | 62.5 |
| **Have any diseases been newly diagnosed since the start of the prurigo?** | 29.0 | **78.4** | 25.0 | 86.2 | 4.0 | 50.0 |
| **What is its possible origin, in your opinion?** | 24.0 | 64.9 | 20.0 | 69.0 | 4.0 | 50.0 |
| **Does this disease negatively affect your sleep?** | 34.0 | **91.9** | 26.0 | 89.7 | 8.0 | 100.0 |
| **Does this disease impact your quality of life?** | 33.0 | **89.2** | 26.0 | 89.7 | 7.0 | 87.5 |
| **Which previous topical therapies have you used to treat the prurigo?** | 37.0 | **100.0** | 29.0 | 100.0 | 8.0 | 100.0 |
| **Which previous systemic therapies have you used to treat the prurigo?** | 37.0 | **100.0** | 29.0 | 100.0 | 8.0 | 100.0 |
| **None** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **2.Itch-related history** |   |   |   |   |   |   |
| **Is it itchy?** | 33.0 | **89.2** | 25.0 | 86.2 | 8.0 | 100.0 |
| **On average, how intense has the itch been during the past 24 h/ three days / week on a scale from 0 to 10? (Recall period might vary; not important here)** | 30.0 | **81.1** | 23.0 | 79.3 | 7.0 | 87.5 |
| **How bad was the itching in the past 24 h /three days/ week on a scale from 0 to 10? (Recall period might vary; not important here)** | 26.0 | 70.3 | 20.0 | 69.0 | 6.0 | 75.0 |
| **Do you have pain, stinging and burning along with itch? (Qualities of itch)** | 31.0 | **83.8** | 26.0 | 89.7 | 5.0 | 62.5 |
| **How often does it itch? (daily, weekly; all day, only at night)** | 31.0 | **83.8** | 25.0 | 86.2 | 6.0 | 75.0 |
| **Do you scratch?** | 28.0 | **75.7** | 25.0 | 86.2 | 3.0 | 37.5 |
| **Does scratching help the itching?** | 19.0 | 51.4 | 17.0 | 58.6 | 2.0 | 25.0 |
| **Does scratching worsen the itching?** | 16.0 | 43.2 | 14.0 | 48.3 | 2.0 | 25.0 |
| **What improves the itching?** | 35.0 | **94.6** | 27.0 | 93.1 | 8.0 | 100.0 |
| **What worsens the itching?** | 33.0 | **89.2** | 25.0 | 86.2 | 8.0 | 100.0 |
| **None** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **3.General history** |
| **Demographics (for example, family status, education, etc)** | 27.0 | 73.0 | 24.0 | 82.8 | 3.0 | 37.5 |
| **Do you have fever, weight loss or sweating at night?** | 29.0 | **78.4** | 24.0 | 82.8 | 5.0 | 62.5 |
| **Do you have or have you had atopic dermatitis, asthma or allergies?** | 36.0 | **97.3** | 28.0 | 96.6 | 8.0 | 100.0 |
| **Do you take any medications on a regular basis?** | 35.0 | **94.6** | 29.0 | 100.0 | 6.0 | 75.0 |
| **Has someone in your family had atopic dermatitis. asthma or allergies?** | 34.0 | **91.9** | 27.0 | 93.1 | 7.0 | 87.5 |
| **What other diseases do you suffer from (for example chronic kidney disease, liver disease)?** | 37.0 | **100.0** | 29.0 | 100.0 | 8.0 | 100.0 |
| **None** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **4. Use of questionnaires** |
| **I use patient questionnaires to assess the presence of depression or anxiety** | 9.0 | 24.3 | 9.0 | 31.0 | 0.0 | 0.0 |
| **I use patient questionnaires to assess the general health** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **I use patient questionnaires to assess the history of prurigo or itch** | 9.0 | 24.3 | 8.0 | 27.6 | 1.0 | 12.5 |
| **I use patient questionnaires to assess the impairment to quality of life** | 22.0 | 59.5 | 20.0 | 69.0 | 2.0 | 25.0 |
| **I use patient questionnaires to assess the intensity of itch** | 23.0 | 62.2 | 19.0 | 65.5 | 4.0 | 50.0 |
| **I use questionnaires to assess the medical history** | 7.0 | 18.9 | 5.0 | 17.2 | 2.0 | 25.0 |
| **None** | 11.0 | 29.7 | 7.0 | 24.1 | 4.0 | 50.0 |
| **II. PHYSICAL EXAMINATION** |
| **5. Dermatological examination** |
| **- Clinical distribution of pruriginous lesions (for example localized/generalized; symmetrical / asymmetrical)** | 36.0 | **97.3** | 29.0 | 100.0 | 7.0 | 87.5 |
| **- Dermatological morphology of pruriginous lesions** | 33.0 | **89.2** | 27.0 | 93.1 | 6.0 | 75.0 |
| **- Number of affected body regions** | 22.0 | 59.5 | 16.0 | 55.2 | 6.0 | 75.0 |
| **- Number of pruriginous lesions** | 18.0 | 48.6 | 15.0 | 51.7 | 3.0 | 37.5 |
| **- Number of pruriginous lesions with excoriations on top** | 12.0 | 32.4 | 11.0 | 37.9 | 1.0 | 12.5 |
| **- Presence of butterfly sign** | 27.0 | 73.0 | 23.0 | 79.3 | 4.0 | 50.0 |
| **- Severity of the disease (for example, few lesions / many lesions)** | 36.0 | 97.3 | 28.0 | 96.6 | 8.0 | 100.0 |
| **- None** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **6.Objective methods routinely used** |
| **- Measurement of pruriginous lesions (with ruler or other device)** | 4.0 | 10.8 | 3.0 | 10.3 | 1.0 | 12.5 |
| **- Monitoring of a targeted lesion (clinically or with photos)** | 15.0 | 40.5 | 12.0 | 41.4 | 3.0 | 37.5 |
| **- Photographic documentation** | 24.0 | 64.9 | 20.0 | 69.0 | 4.0 | 50.0 |
| **- Scores (IGA, prurigo activity score (PAS))** | 14.0 | 37.8 | 12.0 | 41.4 | 2.0 | 25.0 |
| **- None** | 5.0 | 13.5 | 4.0 | 13.8 | 1.0 | 12.5 |
| **7. Routine physical examinations** |
| **- Abdominal palpations** | 8.0 | 21.6 | 7.0 | 24.1 | 1.0 | 12.5 |
| **- Assessment of balance** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **- Assessment of musculature strength** | 1.0 | 2.7 | 0.0 | 0.0 | 1.0 | 12.5 |
| **- Auscultation** | 4.0 | 10.8 | 3.0 | 10.3 | 1.0 | 12.5 |
| **- Brief neurological examination** | 11.0 | 29.7 | 9.0 | 31.0 | 2.0 | 25.0 |
| **- Dermatological examination: Presence of concomitant skin diseases** | 35.0 | **94.6** | 27.0 | 93.1 | 8.0 | 100.0 |
| **- Dermatological inspection of mucous membranes** | 20.0 | 54.1 | 19.0 | 65.5 | 1.0 | 12.5 |
| **- Dermatoscopy of pruriginous lesions** | 13.0 | 35.1 | 9.0 | 31.0 | 4.0 | 50.0 |
| **- Dermographism** | 29.0 | **78.4** | 24.0 | 82.8 | 5.0 | 62.5 |
| **- Measurement of size, weight, BMI** | 11.0 | 29.7 | 9.0 | 31.0 | 2.0 | 25.0 |
| **- Nikolski sign** | 3.0 | 8.1 | 2.0 | 6.9 | 1.0 | 12.5 |
| **- Presence of xerosis cutis (dry skin)** | 30.0 | 81.1 | 25.0 | 86.2 | 5.0 | 62.5 |
| **- None** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **III. SKIN BIOPSIES / SMEARS** |
| **8. Skin biopsies** |
| **On CPG patients with a clinical presence of concomitant dermatoses of any kind** | 17.0 | 45.9 | 15.0 | 51.7 | 2.0 | 25.0 |
| **On CPG patients with a history of signs of a dermatosis (eczema, blisters, erythema)** | 13.0 | 35.1 | 12.0 | 41.4 | 1.0 | 12.5 |
| **On CPG patients with concomitant presence or pustules or granulomas** | 16.0 | 43.2 | 14.0 | 48.3 | 2.0 | 25.0 |
| **On CPG patients with suppurative pruriginous lesions** | 6.0 | 16.2 | 6.0 | 20.7 | 0.0 | 0.0 |
| **On every patient with CPG to rule out underlying dermatoses** | 5.0 | 13.5 | 3.0 | 10.3 | 2.0 | 25.0 |
| **On those with clinically untypical CPG to rule out underlying dermatoses** | 28.0 | **75.7** | 23.0 | 79.3 | 5.0 | 62.5 |
| **On those with CPG of unclear origin to rule out underlying dermatoses** | 21.0 | 56.8 | 19.0 | 65.5 | 2.0 | 25.0 |
| **Never on patients with CPG** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **9. Microbiological smears/culture** |
| **On CPG patients with a clinical presence of concomitant dermatoses of any kind** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **On CPG patients with a history of signs of a dermatosis (eczema, blisters, erythema)** | 3.0 | 8.1 | 2.0 | 6.9 | 1.0 | 12.5 |
| **On CPG patients with concomitant presence or pustules or granulomas** | 19.0 | 51.4 | 15.0 | 51.7 | 4.0 | 50.0 |
| **On CPG patients with suppurative pruriginous lesions** | 19.0 | 51.4 | 14.0 | 48.3 | 5.0 | 62.5 |
| **On every patient with CPG to rule out underlying dermatoses** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **On those with clinically untypical CPG to rule out underlying dermatoses** | 1.0 | 2.7 | 1.0 | 3.4 | 0.0 | 0.0 |
| **On those with CPG of unclear origin to rule out underlying dermatoses** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **Never on patients with CPG** | 8.0 | 21.6 | 7.0 | 24.1 | 1.0 | 12.5 |
| **10. Microscopic work-up** |
| **- Direct and indirect immunofluorescence** | 20.0 | 54.1 | 17.0 | 58.6 | 3.0 | 37.5 |
| **- Electron microscopy** | 1.0 | 2.7 | 1.0 | 3.4 | 0.0 | 0.0 |
| **- Histopathology** | 31.0 | **83.8** | 26.0 | 89.7 | 5.0 | 62.5 |
| **- Intraepidermal nerve fiber density** | 8.0 | 21.6 | 6.0 | 20.7 | 2.0 | 25.0 |
| **- Microbiological smears and culture** | 6.0 | 16.2 | 6.0 | 20.7 | 0.0 | 0.0 |
| **- Microscopic search for scabies - Molecular biology** | 10.0 | 27.0 | 9.0 | 31.0 | 1.0 | 12.5 |
| **- None** | 2.0 | 5.4 | 0.0 | 0.0 | 2.0 | 25.0 |
| **IV. COMPLEMENTARY DIAGNOSTIC EXAMINATIONS** |
| **11. Avoidance of invasive diagnostic procedures** |
| **- CPG of mild itch intensity or mild clinical severity** | 13.0 | 35.1 | 10.0 | 34.5 | 3.0 | 37.5 |
| **- CPG of non-dermatological origin** | 10.0 | 27.0 | 9.0 | 31.0 | 1.0 | 12.5 |
| **- On all CPG patients** | 1.0 | 2.7 | 1.0 | 3.4 | 0.0 | 0.0 |
| **- Older fragile patients** | 6.0 | 16.2 | 6.0 | 20.7 | 0.0 | 0.0 |
| **- Pediatric patients** | 16.0 | 43.2 | 15.0 | 51.7 | 1.0 | 12.5 |
| **- I never try to avoid it; all undergo invasive diagnostic procedures** | 2.0 | 5.4 | 0.0 | 0.0 | 2.0 | 25.0 |
| **12. Patient groups in which laboratory or imagiological diagnostics is performed** |
| **- Depending on family history** | 3.0 | 8.1 | 3.0 | 10.3 | 0.0 | 0.0 |
| **- Depending on the medical history (for example, presence of coughed blood)** | 22.0 | 59.5 | 16.0 | 55.2 | 6.0 | 75.0 |
| **- On all patients with CPG to rule out underlying diseases** | 21.0 | 56.8 | 17.0 | 58.6 | 4.0 | 50.0 |
| **- On patients with CPG who have suffered from it for a year or less** | 9.0 | 24.3 | 7.0 | 24.1 | 2.0 | 25.0 |
| **- On patients with CPG who report night sweating** | 17.0 | 45.9 | 11.0 | 37.9 | 6.0 | 75.0 |
| **- On patients with CPG who report weight loss** | 20.0 | 54.1 | 14.0 | 48.3 | 6.0 | 75.0 |
| **- On patients with CPG of an unknown origin** | 19.0 | 51.4 | 15.0 | 51.7 | 4.0 | 50.0 |
| **- On patients with CPG with very intense pruritus** | 14.0 | 37.8 | 11.0 | 37.9 | 3.0 | 37.5 |
| **- When patients specifically ask for the examinations** | 6.0 | 16.2 | 5.0 | 17.2 | 1.0 | 12.5 |
| **- Never on patients with CPG** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **13. Laboratory examinations regurlarly performed** |
| **- Blood count** | 19.0 | 51.4 | 17.0 | 58.6 | 2.0 | 25.0 |
| **- Complete blood count** | 34.0 | **91.9** | 26.0 | 89.7 | 8.0 | 100.0 |
| **- Electrolytes** | 17.0 | 45.9 | 12.0 | 41.4 | 5.0 | 62.5 |
| **- ESR. CRP** | 27.0 | 73.0 | 23.0 | 79.3 | 4.0 | 50.0 |
| **- Fasting blood sugar level, HbA1c** | 26.0 | 70.3 | 23.0 | 79.3 | 3.0 | 37.5 |
| **- Ferritin** | 24.0 | 64.9 | 21.0 | 72.4 | 3.0 | 37.5 |
| **- IgE, specific IgE** | 28.0 | **75.7** | 23.0 | 79.3 | 5.0 | 62.5 |
| **- Kidney retention parameters (for example, potassium, creatine, urea, GFR)** | 34.0 | **91.9** | 27.0 | 93.1 | 7.0 | 87.5 |
| **- LDH** | 17.0 | 45.9 | 14.0 | 48.3 | 3.0 | 37.5 |
| **- Liver enzymes (for example, GGT, GPT, GOT, alkaline phosphatase, bilirubin)** | 35.0 | **94.6** | 27.0 | 93.1 | 8.0 | 100.0 |
| **- TSH** | 29.0 | **78.4** | 22.0 | 75.9 | 7.0 | 87.5 |
| **- Tumor biomarkers** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **- Urine status** | 15.0 | 40.5 | 14.0 | 48.3 | 1.0 | 12.5 |
| **- None:** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **14. Laboratory examinations based on pathological findings or medical history** |
| **- Antibodies (for example, antimitochondrial antibodies (AMA), pANCA, ANA, SMA, anti-soluble liver antigen antibodies, anti-liver kidney microsomal antibodies , anti-tissue transglutaminase antibodies)** | 16.0 | 43.2 | 15.0 | 51.7 | 1.0 | 12.5 |
| **- Fasting bile acid level** | 9.0 | 24.3 | 9.0 | 31.0 | 0.0 | 0.0 |
| **- Hepatitis (B/C) serology** | 24.0 | 64.9 | 20.0 | 69.0 | 4.0 | 50.0 |
| **- HIV serology, syphilis serology** | 21.0 | 56.8 | 17.0 | 58.6 | 4.0 | 50.0 |
| **- JAK2 mutation status** | 3.0 | 8.1 | 3.0 | 10.3 | 0.0 | 0.0 |
| **- Prostate specific antigen (PSA)** | 8.0 | 21.6 | 8.0 | 27.6 | 0.0 | 0.0 |
| **- Protein electrophoresis, immunofixation** | 18.0 | 48.6 | 16.0 | 55.2 | 2.0 | 25.0 |
| **- Serum tryptase** | 11.0 | 29.7 | 10.0 | 34.5 | 1.0 | 12.5 |
| **- Thyroid diagnostics (for example, parathormone, phosphate, Ca2+, fT3, fT4,…)** | 16.0 | 43.2 | 14.0 | 48.3 | 2.0 | 25.0 |
| **- Vitamin B12, folic acid** | 10.0 | 27.0 | 9.0 | 31.0 | 1.0 | 12.5 |
| **- None** | 4.0 | 10.8 | 2.0 | 6.9 | 2.0 | 25.0 |
| **15. Imagiological examinations routinely performed** |
| **- Chest x-ray** | 21.0 | 56.8 | 17.0 | 58.6 | 4.0 | 50.0 |
| **- Cranial CT or MRI** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **- CT of abdomen** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **- CT of thorax** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **- Gastroscopy, colonoscopy** | 2.0 | 5.4 | 2.0 | 6.9 | 0.0 | 0.0 |
| **- PET-CT** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **- Sonography of abdomen** | 15.0 | 40.5 | 14.0 | 48.3 | 1.0 | 12.5 |
| **- Sonography of lymph node stations** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **- Sonography of the thyroid gland** | 3.0 | 8.1 | 3.0 | 10.3 | 0.0 | 0.0 |
| **- Whole body MRI** | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| **- None** | 12.0 | 32.4 | 9.0 | 31.0 | 3.0 | 37.5 |
| **16. Additional examinations** |
| **- Allergy test (prick test, epicutaneous test)** | 12.0 | 32.4 | 11.0 | 37.9 | 1.0 | 12.5 |
| **- Fructose intolerance test** | 2.0 | 5.4 | 2.0 | 6.9 | 0.0 | 0.0 |
| **- Lactose intolerance test** | 5.0 | 13.5 | 5.0 | 17.2 | 0.0 | 0.0 |
| **- Sorbitol intolerance test** | 4.0 | 10.8 | 4.0 | 13.8 | 0.0 | 0.0 |
| **- None** | 22.0 | 59.5 | 16.0 | 55.2 | 6.0 | 75.0 |
| **17. Involvement of other medical disciplines** |
| **- Allergology** | 9.0 | 24.3 | 7.0 | 24.1 | 2.0 | 25.0 |
| **- Clinical Psychology** | 8.0 | 21.6 | 8.0 | 27.6 | 0.0 | 0.0 |
| **- Gynecology** | 3.0 | 8.1 | 3.0 | 10.3 | 0.0 | 0.0 |
| **- Internal medicine** | 17.0 | 45.9 | 15.0 | 51.7 | 2.0 | 25.0 |
| **- Neurology** | 8.0 | 21.6 | 5.0 | 17.2 | 3.0 | 37.5 |
| **- Oncology** | 1.0 | 2.7 | 1.0 | 3.4 | 0.0 | 0.0 |
| **- Pain specialists** | 4.0 | 10.8 | 3.0 | 10.3 | 1.0 | 12.5 |
| **- Pediatrics** | 2.0 | 5.4 | 2.0 | 6.9 | 0.0 | 0.0 |
| **- Phlebology** | 1.0 | 2.7 | 1.0 | 3.4 | 0.0 | 0.0 |
| **- Psychiatry/Psychosomatics** | 19.0 | 51.4 | 18.0 | 62.1 | 1.0 | 12.5 |
| **- Radiology** | 7.0 | 18.9 | 6.0 | 20.7 | 1.0 | 12.5 |
| **- Urology** | 2.0 | 5.4 | 2.0 | 6.9 | 0.0 | 0.0 |
| **- None** | 9.0 | 24.3 | 5.0 | 17.2 | 4.0 | 50.0 |

**Supplementary Table 2**. **Results of the recommendations voting** are shown for the consensus conference and post-meeting survey. The wording of the recommendations can be consulted in the guideline. A consensus could be reached for all items.

\*1 expert abstained from voting and is not considered in the total member count presented on the table; \*\*Post-delphi survey after modification: A total of 33 experts voted on the recommendations

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Members attending consensus meeting****(n=24)** | **Members not attending consensus meeting (n=10)\*** | **Total (n=34)\*** |
| **DIAGNOSTICS** | **Yes (%)** | **No (%)** | **Yes (%)** | **No (%)** | **Yes (%)** | **No (%)** |
|  **Chapter 9: History of chronic prurigo\*\***  |  |  |  |  | 100 | 0.0 |
| **Chapter 10: General history** | 100 | 0 | 100 | 0 | 100.0 | 0.0 |
| **Chapter 11: Clinical assessment** | 100 | 0 | 90 | 10 | 97.1 | 2.9 |
| **Chapter 12: Questionnaires** | 100 | 0 | 100 | 0 | 100.0 | 0.0 |
| **Chapter 13: Diagnostic approach (physical examination. lab, radiology, microbiology, referral to psychological, psychosomatic or psychiatric assessment)** | 96 | 4 | 100 | 0 | 97.1 | 2.9 |
| **Chapter 14: Skin biopsy** | 92 | 8 | 100 | 0 | 94.1 | 5.9 |
| **THERAPY** | **Yes (%)** | **No (%)** | **Yes (%)** | **No (%)** | **Yes (%)** | **No (%)** |
| **Chapter 16: Causative therapy** | 96 | 4 | 100 | 0 | 97.1 | 2.9 |
| **Chapter 17: Emollients** | 100 | 0 | 100 | 0 | 100.0 | 0.0 |
| **Chapter 18: Topical steroids, calcineurin Inhibitors** | 96 | 4 | 90 | 10 | 94.1 | 5.9 |
| **Chapter 19: Cryotherapy, intralesional corticosteroids** | 92 | 8 | 90 | 10 | 91.2 | 8.8 |
| **Chapter 20: Capsaicin** | 87.5 | 12.5 | 100 | 0 | 91.2 | 8.8 |
| **Chapter 21: UV therapy\*\*** |  |  |  |  | 90.9 | 9.1 |
| **Chapter 22: Antihistamines** | 96 | 4 | 90 | 10 | 94.1 | 5.9 |
| **Chapter 23: Gabapentinoids** | 83.0 | 17.0 | 100 | 0 | 88.2 | 11.8 |
| **Chapter 24: Immunosuppressants (Cyclosporine, MTX, etc)** | 100 | 0 | 90 | 10 | 97.1 | 2.9 |
| **Chapter 24: Immunosuppressants (Thalidomid, Lenalidomid)** | 79.0 | 21.0 | 100 | 0 | 85.3 | 14.7 |
| **Chapter 25: Opioid modulators (mu antagonists, kappa agonists)** | 100 | 0 | 100 | 0 | 100.0 | 0.0 |
| **Chapter 26: Neurokinin 1 receptor antagonists ((fos)aprepitant)** | 87.5 | 12.5 | 100 | 0 | 91.2 | 8.8 |
| **Chapter 26: Neurokinin 1 receptor antagonists (serlopitant)\*\*** |  |  |  |  | 93.9 | 6.1 |
| **Chapter 27: Biologics and small molecules** | 100 | 0 | 80 | 20 | 94.1 | 5.9 |
| **Chapter 27: Nemolizumab\*\*** |   |   |   |   | 97.0 | 3.0 |
| **Chapter 28: Antidepressants** | 96 | 4 | 100 | 0 | 97.1 | 2.9 |
| **Chapter 29: Psychosomatic therapy** | 100 | 0 | 90 | 10 | 97.1 | 2.9 |
| **Treatment Ladder (Figure 3)** | 96 | 4 | 100 | 0 | 97.1 | 2.9 |